Klaus WirthProf. Dr. Klaus Wirth, Medical Doctor, PhD, has served as Chief Scientific Officer and Managing Director of Mitodicure since 2022. He was previously Senior Researcher at Sanofi in Germany which he joined in 1984. Klaus worked as a pharmacologist in te fields of cardiovascular, bradykinin antagonism, cerebral blood flow, stroke, heart failure, arrhythmias, sodium-calcium exchanger NCX blockers, endocrinology, diabetes, obstructive sleep apnea, dysphagia, and immunology. Approximately 70 patents are attributable to his work, as well as five clinical developmental projects, one of which Firazyr(TM), a drug for the treatment of acute attacks of hereditary angioedema, has reached the market. Klaus was co-founder of KOSA Pharma GmbH. He is adjunct professor at the Institute of Pharmacology at Goethe University Frankfurt, Germany. Read More Read Less